How do GLP-1 drugs work? - Reddit

What is GLP-1 and why does it matter?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the small intestine and colon in response to food intake. Its natural role is to signal the presence of nutrients to multiple downstream systems:

• It stimulates insulin secretion from pancreatic beta cells (glucose-dependently — only when blood sugar is elevated).
• It suppresses glucagon secretion, reducing hepatic glucose output.
• It slows gastric emptying, prolonging the feeling of fullness after eating.
• It activates GLP-1 receptors in the hypothalamus and brainstem, reducing appetite and increasing satiety signals.

The problem with endogenous GLP-1 is that it degrades rapidly — its half-life in circulation is roughly two minutes, enzymatically cleaved by dipeptidyl peptidase-4 (DPP-4). This means natural GLP-1 acts locally and transiently, not as a sustained systemic signal.

What do GLP-1 receptor agonists do differently?

GLP-1 receptor agonists are engineered analogs of natural GLP-1, modified to resist DPP-4 cleavage and extend their half-life dramatically. Semaglutide, for example, has a half-life of approximately one week — enabling once-weekly subcutaneous injection while maintaining sustained receptor activation.

This sustained activation changes the pharmacological picture substantially. Instead of a brief post-meal signaling pulse, GLP-1 receptor agonists provide continuous receptor engagement across multiple biological sites simultaneously.

Brain: appetite and reward circuitry

GLP-1 receptors are expressed in the hypothalamus (particularly the arcuate nucleus, which governs hunger and satiety signaling), the brainstem, and areas involved in reward and motivation. Activation of hypothalamic GLP-1 receptors suppresses neuropeptide Y (NPY) and agouti-related peptide (AgRP) — the primary hunger-promoting neuropeptides — while supporting the activity of pro-opiomelanocortin (POMC) neurons, which signal satiety.

Critically, GLP-1 receptor agonists also reduce reward-driven eating. They attenuate the motivational salience of high-calorie, high-reward foods — an effect mediated through dopaminergic and opioid circuits in the mesolimbic system. This is why many patients report that food simply “becomes less interesting” on GLP-1 therapy — this is a pharmacological effect, not willpower.

Stomach: gastric emptying

GLP-1 receptor agonists slow gastric emptying — the rate at which food moves from the stomach into the small intestine. This extends postprandial fullness and reduces the amplitude of blood glucose spikes after meals. From a weight management standpoint, it means patients feel satisfied with smaller portions for longer.

Pancreas: insulin and glucagon

GLP-1 receptor agonists increase insulin secretion from pancreatic beta cells in a glucose-dependent manner — they amplify the pancreatic response to elevated blood sugar, but they do not cause insulin release when glucose is normal. This glucose-dependence is why hypoglycemia is uncommon with GLP-1 monotherapy. Simultaneously, glucagon secretion is suppressed, reducing hepatic glucose production.

Semaglutide vs. tirzepatide: what does the dual mechanism add?

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is the other major incretin hormone, secreted from K-cells in the upper small intestine. Its effects complement GLP-1: it amplifies insulin secretion, supports adipocyte metabolism, and appears to enhance the central appetite suppression produced by GLP-1 receptor activation.

In the SURMOUNT-1 trial, tirzepatide produced mean weight reductions of up to 22.5% at 68 weeks — somewhat greater than semaglutide's approximately 15% in the STEP-1 trial at 68 weeks, though direct head-to-head comparisons are ongoing. Individual responses vary considerably, and the clinical decision between the two agents involves the patient’s history, tolerability profile, and clinician judgment — not just efficacy data.

What does “compounded” semaglutide and tirzepatide mean?

The GLP-1 medications PepScribe’s clinical team works with are compounded by licensed 503A pharmacies in the USA — not FDA-approved branded drugs. Compounded peptides are not FDA-approved; they are prepared by licensed compounding pharmacies under 503A oversight, with no hidden overseas supply chain.

This is a regulatory distinction that matters for how the medication is made and overseen — not a statement of equivalence to any branded product. Licensed 503A compounding in the USA requires sterility testing and pharmacist oversight, which is meaningfully different from gray-market or overseas sources.

These medications require a prescription from a licensed clinician after a clinical review. The clinician determines whether GLP-1 therapy is appropriate, which agent and dose to start at, and how to manage the escalation schedule.

Do GLP-1 patches and OTC supplements work the same way?

Alongside the growth in legitimate GLP-1 prescribing, a market has emerged for OTC products marketed as “GLP-1 supplements” or “natural GLP-1 boosters.” These products do not contain semaglutide, tirzepatide, or any other GLP-1 receptor agonist. They are not the same class of compound, do not work by the same mechanism, and have not been shown to produce the appetite or weight effects associated with prescription GLP-1 therapy.

If you have encountered these products, the honest summary is: the mechanism behind GLP-1 drugs requires receptor agonism by a structurally specific peptide that resists GI degradation. No OTC supplement or transdermal patch delivers that. The legitimate path to GLP-1 therapy is a clinician prescription, a licensed compounding pharmacy, and clinical monitoring.

Frequently asked questions